The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period

Trial Profile

The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Interstitial cystitis
  • Focus Registrational; Therapeutic Use
  • Acronyms LEADERSHIP 301
  • Sponsors Aquinox Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to an Aquinox Pharmaceuticals media release, as of August 7, 2017, 195 patients have been enrolled in this trial. Top-line data from this trial are expected in the third quarter of 2018.
    • 09 May 2017 According to an Aquinox Pharmaceuticals media release, the company plans to provide an enrollment update with additional guidance on expected timing of top-line data at its mid-year financial conference call in early August 2017.
    • 09 Mar 2017 As at March 8, 2017, a total of 64 patients have been enrolled in this trial, according to an Aquinox Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top